PriceTargets.com logo

Moleculin Biotech - MBRX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $24.00
  • Forecasted Upside: 1,311.76%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.70 As of 12/30/2024 12:57 PM ET
▲ +0.05 (3.03%)

This chart shows the closing price for MBRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Moleculin Biotech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MBRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MBRX

Analyst Price Target is $24.00
▲ +1,311.76% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Moleculin Biotech in the last 3 months. The average price target is $24.00, with a high forecast of $40.00 and a low forecast of $8.00. The average price target represents a 1,311.76% upside from the last price of $1.70.

This chart shows the closing price for MBRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Moleculin Biotech. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/9/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/7/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/5/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/4/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/3/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/1/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/30/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/12/2024Maxim GroupLower TargetBuy ➝ Buy$20.00 ➝ $8.00
4/12/2024Roth MkmReiterated RatingBuy ➝ Buy$40.00
3/26/2024Maxim GroupLower TargetBuy ➝ Buy$45.00 ➝ $20.00
12/14/2023HC WainwrightReiterated RatingBuy$45.00
4/18/2023Roth MkmReiterated RatingBuy$240.00
3/24/2023OppenheimerReiterated RatingOutperform$75.00
11/11/2022OppenheimerLower Target$210.00 ➝ $75.00
8/16/2022Roth CapitalLower Target$435.00 ➝ $240.00
7/18/2022OppenheimerReiterated RatingOutperform$210.00
6/25/2020OppenheimerReiterated RatingBuy$180.00
6/9/2020Maxim GroupInitiated CoverageBuy$270.00
4/28/2020OppenheimerInitiated CoverageBuy$180.00
4/15/2020Maxim GroupInitiated CoverageBuy$270.00
4/9/2020Maxim GroupInitiated CoverageBuy$270.00
(Data available from 12/30/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/3/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/3/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/2/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2024
  • 2 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2024

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Moleculin Biotech logo
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.
Read More

Today's Range

Now: $1.70
Low: $1.65
High: $1.73

50 Day Range

MA: $2.43
Low: $1.65
High: $3.09

52 Week Range

Now: $1.70
Low: $1.50
High: $15.75

Volume

10,137 shs

Average Volume

35,770 shs

Market Capitalization

$5.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.87

Frequently Asked Questions

What sell-side analysts currently cover shares of Moleculin Biotech?

The following equities research analysts have issued research reports on Moleculin Biotech in the last year: Maxim Group, Roth Mkm, and StockNews.com.
View the latest analyst ratings for MBRX.

What is the current price target for Moleculin Biotech?

0 Wall Street analysts have set twelve-month price targets for Moleculin Biotech in the last year. Their average twelve-month price target is $24.00, suggesting a possible upside of 1,311.8%. Roth Mkm has the highest price target set, predicting MBRX will reach $40.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $8.00 for Moleculin Biotech in the next year.
View the latest price targets for MBRX.

What is the current consensus analyst rating for Moleculin Biotech?

Moleculin Biotech currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MBRX will outperform the market and that investors should add to their positions of Moleculin Biotech.
View the latest ratings for MBRX.

What other companies compete with Moleculin Biotech?

Other companies that are similar to Moleculin Biotech include GeoVax Labs, Athira Pharma, Affimed, Tenax Therapeutics and Senti Biosciences. Learn More about companies similar to Moleculin Biotech.

How do I contact Moleculin Biotech's investor relations team?

Moleculin Biotech's physical mailing address is 5300 MEMORIAL DRIVE SUITE 950, HOUSTON TX, 77007. The company's listed phone number is (713) 300-5160 and its investor relations email address is [email protected]. The official website for Moleculin Biotech is www.moleculin.com. Learn More about contacing Moleculin Biotech investor relations.